| COMPANY | YEAR | LOCATION | BUSINESS MODEL | MANAGEMENT | TOT-M€ | LAST-M€ | FOCUS | STAGE |
|---|
Abcys
Profile +
www.abcysonline.com | 1999 | IDF
Paris | Design, Reagents
Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties, Gemstem
Mission: to design, manufacture and distribute biotechnology reagents, and to develop own research on Stem Cells
Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry, Diagnostic industry
Age: 18 year(s) | Start-up |
Managing Dir.-CEO: Martin (Thierry) [born 1961]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): undisclosed
Communication : no website corporate information or press release since 2006 | n.a. | n.a. | Cell | Trade |
AB Science
Profile +
www.ab-science.com | 2001 | IDF
Paris | Discovery, Drugs
Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases
Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals
Clients: Prescribers, Veterinarians
Age: 17 year(s) | Start-up |
Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Guy (Laurent)
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€)
note (September 2011) : sales are derived from masitinib in veterinary practice | 30.0 (estim.) | n.a. | Cancers | Clinical |
Adocia
Profile +
www.no-website.net | 2005 | Rhône-Alpes
Lyon | Discovery, Drugs
Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone
Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes
Clients: Pharmaceutical industry
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)]
Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies]
Fin.Dir.-CFO: Danaguezian (Valérie)
BusDev: Soula (Rémi)
Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage [died in 2011]), InnoBio, SHAM (Société Hospitalière d'Assurances Mutuelles) | 55.0 | 27.4 | Multiple | Clinical |
Advicenne Pharma
Profile +
www.advicenne.com | 2007 | Méditerranée
Castries
(near Nîmes) | Discovery, Drugs
Key words: CNS, Pediatry, Emergent diseases
Mission: development and marketing of drugs for pediatric use mainly for the treatment of Central Nervous System Diseases (including autism, feeding behaviours dysfunctions and neurodegenerative disorders)
Clients: undisclosed
Age: 11 year(s) | Personal venture |
Managing Dir.-CEO: Granier (Luc-André) [founder, born 1954, Ph.D., M.D., ex-Forenap, Eli Lilly, Syntem]
Oper.Dir.-COO: Roussel-Maupetit (Caroline) [born 1969, Eng., ex-Syntem (co-founder), Protéine Performance]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.13 M€), but CDC Entreprises with a board member
Communication : website under development (March, September 2011, October 2012) | n.a. | n.a. | CNS | Preclin |
Affichem
Profile +
www.affichem.com | 2002 | Midi-Pyrénées
Toulouse | Design, Drugs
(also Design, Diagnostics)
Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases
Mission: to develop drug candidates based on proprietary new family of compounds derived from sterols, Dendrogenines A and B, in cancer and neurodegenerative diseases
Clients: Prescribers
Age: 16 year(s) | Start-up | Managing Dir.-CEO: Silvente (Stéphane) [co-founder, born 1968, MBA, Ms. International Business, also chairman]
Sc.Dir.-CSO: Poirot (Marc) [co-founder, born 1960, also Inserm, Ph.D. chemical biology]
Pharm.Dir.: Silvente-Poirot (Sandrine) [co-founder, also Inserm, Ph.D. molecular pharmacology]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, undisclosed (opening of capital proposed to individuals in 2012, up to 8.6%) | n.a. | n.a. | Cancers | Preclin |
Agate Bioservices
Profile +
www.agatebioservices.com | 2005 | Méditerranée
Alès
(near Nîmes) | Contract, Services
(also, Discovery, Targets)
Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus, BacTen
Mission: to provide third parties with services ranging from gene cloning to protein (or virus) production (resp. purification), acting as a vector developer, either for protein production or for gene transfer, as well as a manufacturing partner, to to develop new systems and technologies in the gene expression, gene transfer and delivery areas
Clients: Pharmaceutical industry, Biotech, Research labs
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Chaabihi (Hassan) [founder, born 1962, Ph.D. molecular biology, ex-Protéines Performance, Quantum Biotechnologies]
Sc.Dir.-CSO: Chaabihi (Hassan)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.008 M€)
Communication : no website news update since November 2006 | n.a. | n.a. | Target | Preclin |
Aisa Therapeutics
Profile +
www.aisa-tx.com | 2005 | IDF
Évry
(near Paris) | Discovery, Drugs
Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress
Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability
Clients: pharmaceutical industry, veterinary industry
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: d'Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Loumeau (Jean-François) [M.D., MBA]
Financers (Hist.): Critt Chimie, Anvar | n.a. | n.a. | Inflammation | Preclin |
Alfact Innovation
Profile +
alfactinnovation.com | 2006 | IDF
Paris | Discovery, Drugs
Key words: Liver Failure, Liver Cancer
Mission: to develop biopharmaceuticals for liver diseases
Clients: undisclosed
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Amouyal (Gilles) [born 1957, M.D., Ph.D.]
Sc.Dir.-CSO: Bréchot (Christian) [M.D., Ph.D., V.P. Biomérieux, ex-Inserm]
Oper.Dir.-COO: Mariau (Jérémie) [M.Sc. human genetic, Eng. Supagro]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): unknown (registered capital 2008 = 1.48 M€) | n.a. | n.a. | Cancers | Preclin |
Alizé Pharma
Profile +
www.alz-pharma.com | 2007 | Rhône-Alpes
Ecully
(near Lyon) | Discovery, Drugs
Key words: Diabetes, Leukaemia, Recombinant L-asparaginase
Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development)
Clients: Pharmaceutical industry
Age: 11 year(s) | Start-up |
Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Delale (Thomas)
Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€) | 4.8 | 3.0 | Multiple | Preclin |
Ambiotis
Profile +
www.ambiotis.com | 2007 | Midi-Pyrénées
Toulouse | Contract, Services (also, Research, Drugs)
Key words: Validation, Anti-inflammatory, Immunostimulatory, Biomarkers
Mission: to provide preclinical testing services (cellular and animal experiments) for anti-inflammatory and immunostimulatory assays of third parties, and to undertake own research specialized in the study of lipoxins, resolvins and protectins
Clients: Pharmaceutical industry, Cosmetics, Nutraceutics, Agro-food
Age: 11 year(s) | Personal venture |
Managing Dir.-CEO: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. immunology, Ms. Management (Toulouse)]
Sc.Dir.-CSO: Dubourdeau (Marc)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.04 M€) | n.a. | n.a. | Inflammation | Subcontractor |
Anaconda Pharma
Profile +
www.anacondapharma.com | 2003 | IDF
Paris | Discovery, Drugs
Key words: Protein interactions, Condyloma, Anti-viral
Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins
Clients: Prescribers
Age: 14 year(s) | Spin-off |
Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset]
Sc.Dir.-CSO:
Med.Dir.: Compère (Delphine) [Ph.D. organic chemistry, ex-Pfizer, Cerep]
Fin.Dir.-CFO: Bali (Ismahane) [Ms accounting, ex-Audit and Diagnostic]
BusDev:
Financers (Hist.): privately owned (private investors) | 3.6 | 2.6 | Cancers | Preclin |
Aptys Pharmaceuticals
Profile +
www.aptys-pharmaceuticals.com | 2002 | Centre
Clermont-Ferrand | Contract, Research
(also, Delivery, Drugs)
Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery
Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow
Clients: Pharmaceutical industry, Biotechs
Age: 15 year(s) | Spin-off |
Managing Dir.-CEO: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides]
Sc.Dir.-CSO: Boutignon (François)
Techn.Dir.-CTO: Barres (Thomas) [Ms.Sc., Pharm. D., ex-LPH Industries]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Sofimac Partners, Crédit Agricole Centre France, privately owned (registered capital 2007 = 0.10 M€) | 0.5 | 0.5 | Multiple | Preclin |
Ariana Pharmaceuticals
Profile +
www.arianapharma.com | 2003 | IDF
Paris | Contract, Knowledge
Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays
Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties
Clients: Pharmaceutical industry, Biotechs
Age: 15 year(s) | Spin-off |
Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets]
Sc.Dir.-CSO:
Tech.Dir.-CTO: Kuras (Mariana) [Ph.D. biophysics, ex-Biosystems, Pfizer]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation | 1.5 | 1.5 | Data | Subcontractor |
Aterovax
Profile +
www.aterovax.com | 2006 | IDF
Paris | Discovery, Development, Diagnostics and Immunology-vaccines
Key words: Tests, Atherosclerosis, sPLA2 Activity Test, Atherosclerosis Risk Assessment, Biomarker for Cardiovascular Risk Evaluation and Prevention, Secreted Phospholipase A2 Activity, In Vitro Diagnostic Assay, Immunotherapy
Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis
Clients: undisclosed
Age: 12 year(s) | Start-up |
Managing Dir.-CEO: Surun (Dominique) [M.D., MBA (CPA), ex-Meda Pharma, Janssen Cilag, 3M]
Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.]
Fin.Dir.-CFO:
Regul.Dir.: Doceur (Paula) [Ph.D.]
BusDev:
Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€)
Communication : website under re-construction (October 2012), legal undetailed changes at the end of 2011 - beginning 2012 (new chairman of the board, capital increase) | n.a. | n.a. | Cardiovasc | 1st product soon available |
Atlantic Bone Screen
Profile +
www.atlantic-bone-screen.com | 2005 | Bretagne
Nantes | Contract, Services
Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO
Mission: to offer in vitro and in vivo (patented animal models) services dedicated to validation of proof of concept in osteoarticular pathologies, and (Atlanchim) to act as a subcontractor for the synthesis of new molecules
Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Porcher (Elisabeth) [MBA, ex-Eurocopter]
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€), internal growth (no outside investors searched) | n.a. | n.a. | Inflammation | Subcontractor |
Aureus Sciences
Profile +
www.aureus-sciences.com | 2000 | IDF
Paris | Contract, Knowledge
Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE
Mission: to provide knowledge management solutions to accelerate life science discovery for third parties
Clients: Pharmaceutical industry, Biotechs
Age: 18 year(s) | Start-up |
Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier
Sc.Dir.-CSO:
Dev.Dir.: Barberan (Olivier) [Ph.D.]
Fin.Dir.-CFO:
MktgComm:
BusDev:
Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM
Note : the news thread astutely mixes own events and general R&D major findings external to the company | n.a. | n.a. | Data | Subcontractor |
B Cell Design
Profile +
www.b-cell-design.com | 2008 | Centre
Limoges | Discover, Drugs
Key words: Humanised antibodies
Mission: to develop, manufacture humanised IgA and IgG antibodies from genetically modified mice
Clients: Clinical labs, Research labs, Medical imaging, Therapists
Age: 10 year(s) | Personal venture |
Managing Dir.-CEO: Sainte-Laudy (Jean) [born 1946, Ph.D. immunology, ex-Pasteur Cerba]
Sc.Dir.-CSO: Cuvillier (Armelle) [Ph.D. health biology]
Techn.Dir.-CTO: Champier (Gaël) [M.S. biotechnologies]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Limousin Participation, Limousin Expansion, Limousin Business Angels | 0.1 | 0.1 | Cancers | Proof-of-Concept |
BioAlliance Pharma
Profile +
www.bioalliancepharma.com | 1997 | IDF
Paris | Discovery, Drugs
(also Delivery, Drugs)
Key words: Cancer, HIV, Opportunistic infections
Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE's ans drug delivery improvements
Clients: Prescribers
Age: 21 year(s) | Start-up |
Managing Dir.-CEO: Greciet (Judith) [Pharm.D., ex-Eisai, Wyeth, LFB, Zeneca, Pharmacia]
Oper.Dir.-COO:
Med.Dir.-CMO: Attali (Pierre) [M.D., M.Sc., ex-Synthelabo, Sanofi, OSMO (co-founder), Molecular Engines Laboratories, Urogene]
Sc.Dir.-CSO: Kayitalire (Louis) [M.D., Institut Gustave Roussy, ex-Eli Lilly, B.M.S., Cephalon]
Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young]
SalesMktg: Dupré (Florence)
BusDev:
Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public
Note : Financière de la Montagne (a company of family Besançon-Trébouta, previously holding Laboratoires Delagrange, part of Synthelabo, acquired by Sanofi) holds 10% of capital in December 2012 | 107.6 | 16.6 | Cancers | Launch |
Biocortech
Profile +
www.biocortech.com | 2001 | IDF
Paris | Discovery, Drugs
Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate
Mission: to develop novel biomarkers and treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits
Clients: Pharmaceutical industry (own development, up to clinical trials)
Age: 16 year(s) | Spin-off |
Managing Dir.-CEO: Weissmann-Pujol (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. neurobiology, ex-Roussel Uclaf, CNRS]
Sc.Dir.-CSO: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS]
Fin.Dir.-CFO:
BusDev: Allemand (Frédéric) [M.D. cardiology, ex-Hybrigenics, Bayer, Syngenta, Biovector Therapeutics, Hybrigenics, Genopole Entreprises, Medincell, Surfactis, Phenopro]
Financers (Hist.): Institut Pasteur, business angels | n.a. | n.a. | CNS | Preclin |
BioCydex
Profile +
www.biocydex.com | 2002 | Aquitaine
Poitiers | Delivery, Drugs
(also, Contract, Services)
Key words: Ophthalmology, Cyclodextrins
Mission: to develop new compound formulations in ophthalmology, cancerology, and organ preservation during transplantation
Clients: Pharmaceutical industry (up to clinical stage)
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Belgsir (El Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS]
Sc.Dir.-CSO: Cenatiempo (Yves) [co-founder, also board chairman till 2008, born 1950, Prof. biochemistry (Poitiers)]
Fin.Dir.-CFO: Marembaud (Olivier) [born 1952, Engineer, ex-Frantour, Kelois, SNCF]
BusDev:
Financers (Hist.): Oseo | n.a. | n.a. | Ophthamo | Preclin |
Biométhodes
Profile +
www.biomethodes.com | 1997 | IDF
Évry
(near Paris) | Contract, Manufacturing
(also Design, Drugs)
Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme
Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics
Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food
Age: 20 year(s) | Personal venture |
Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio]
Sc.Dir.-CSO: Winter (Bruno) [Ph.D., ex-AB Enzymes]
Techn.Dir.-CTO: Langvad (Niels) [ex-Biodiesel (co-founder)]
Fin.Dir.-CFO: Kazandjian (Raffy) [ex-CDC-Innovation Partners]
BusDev:
Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC) | n.a. | n.a. | Haemophilia | Trade |
Biom'up
Profile +
www.biomup.com | 2005 | Rhône-Alpes
Saint-Priest
(near Lyon) | Development, Biomaterials & Medical devices
(also, Contract, Manufacturing)
Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction
Mission: to develop and manufacture innovative biopolymers, such as collagens, for implantable Medical Devices, with a special focus on long term applications, and to design customized Purification Tools, particularly in affinity chromatography
Clients: Pharmaceutical industry, Cosmetic industry, Biotechs
Age: 13 year(s) | Spin-off |
Managing Dir.-CEO: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa],
Sc.Dir.-CSO: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also COO]
Fin.Dir.-CFO:
SalesDir.: Francy (Philippe) [Sup de Co]
Financers (Hist.): privately owned, Créalys, SHAM, Sofimac Partners, Ameliane, Aquasourça, InnoBio, Viveris Management, OTC Asset Management | 11.3 | 6.8 | Collagen | Trade |
BioProtein Technologies
Profile +
www.bioprotein.com | 1998 | IDF
Jouy-en-Josas
(near Paris) | Contract, Manufacturing
Key words: Therapeutic proteins, Gene expression, Transgenic rabbits
Mission: to provide third parties with production of recombinant therapeutic proteins and vaccines in the milk of transgenic rabbits, as a fully integrated service from gene expression to industrial production of purified proteins and vaccines
Clients: Pharma industry, Research labs, Biotechs
Age: 20 year(s) | Personal venture |
Managing Dir.-CEO: Lignel (Jean)
Sc.Dir.-CSO: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma]
Fin.Dir.-CFO:
BusDev: Fouassier (Alexandre) [Eng. INRA, M.Sc. biochemistry, also COO]
Financers (Hist.): Société Générale A.M., Gilde, Creagro, Iwic, Anvar | 11.0 | 0.5 | Multiple | Preclin |
BioQuanta
Profile +
www.bioquanta.com | 2003 | IDF
Paris | Contract, Research
(also, Discovery, Drugs)
Key words: Clinical biology, Biochemistry, Molecular modeling, In-silico Toxicity Prediction, In-vitro metabolic Exploration, Diagnostic kit and drug development
Mission: to promote predictive and personalized medicine
Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Rabeuf (Rémi) [M.Sc. biology, MBA, ex-Roche (20 years)]
Sc.Dir.-CSO:
Oper.Dir.-COO:
Fin.Dir.-CFO:
BusDev: Guidon (Romain) [MBA]
Financers (Hist.): privately-owned (undisclosed private investors) | 0.5 | 0.5 | Cancers | Patents |
BioSystems International
Profile +
www.biosys-intl.com | 2004 | IDF
Évry
(near Paris) | Design, Diagnostics
Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins
Mission: to discover and validate biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations
Clients: Pharmaceutical industry (AstraZeneca), Biotechs
Age: 13 year(s) | Spin-off |
Managing Dir.-CEO: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank
Sc.Dir.-CSO: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH]
Tech.Dir.-CTO: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter]
Fin.Dir.-CFO: Hollai (Andrea) [MBA, ex-Hungarian Journalist's Federation]
BusDev:
Financers (Hist.): Société Générale
Note : a susidiary (research) in Hungary | 6.5 | 3.5 | Multiple | Trade |
BMSystems (Bio-Modeling)
Profile +
www.bmsystems.net | 2004 | IDF
Paris | Discovery, Hub
Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off
Mission: to help clients run their life sciences R&D programs better, faster, cheaper and safer by applying CADI methodologies and tools, an operational systems biology approach (mainly in the fields of infectious diseases, neurology, psychiatry, oncology, dermatology and innovative bioprocesses)
Clients: R&D departments (on a partnering basis), Financers (in case of spin-off)
Age: 14 year(s) | Start-up |
Managing Dir.-CEO: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey]
Sc.Dir.-CSO: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium]
Med.Dir.-CMO: Dine (Gérard) [M.D., Ph.D.]
I.T.Dir.-CIO: Santamaria (Pablo) [Eng. Centrale, ex-Formitel, Glaxo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately-owned (no search for external investors) | n.a. | n.a. | Multiple | Proof-of-Concept |
Carmat
Profile +
www.carmatsas.com | 2008 | IDF
Vélizy
(near Paris) | Development, Device
Key words: Artificial heart, Computer simulation, Electronic captors, Bioprothesis
Mission: to clinically develop, then market a fully implantable artificial heart for patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible
Clients: Hospitals
Age: 10 year(s) | Spin-off |
Managing Dir.-CEO: Conviti (Marcello) [born 1952, Ph.D., MBA, ex-Edwards Lifesciences, Sorin]
Sc.Dir.-CSO: Carpentier (Alain) [born 1933, co-founder, M.D. (surgery), Hospital Professor]
Fin.Dir.-CFO:
MktgComm: Leroy (Valérie) [Ms. Mktg (Paris), ex-Toshiba Systèmes, Medtronic, Edwards Lifesciences]
BusDev:
Financers (Hist.): Truffle Capital, Oseo, EADS
Note : company first sourced as a J.V. Carpentier-Matra, in 1993 (company name, Carmat = Carpentier + Matra)
Note : Internet showroom, available since June 2009 | 52.8 | 29.3 | Cardiovasc | Preclin |
Cellectis
Profile +
www.cellectis.com | 2000 | IDF
Romainville
(near Paris) | Discovery, Therapy
(also Research, Subcontractor)
Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.)
Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs
Competitors: Applied Biosystems, 454 Life Sciences, Celera
Age: 18 year(s) | Spin-off |
Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology], also chairman
Oper.Dir.-COO: Simon (Mathieu) [M.D., ex-Wyeth, Pierre Fabre]
Sc.Dir.-CSO: Duchateau (Philippe) [Ph.D. science]
Tech.Dir.-CTO: Epinat (Jean-Charles) [Ph.D. science, ex-Institut Pasteur]
Fin.Dir.-CFO: Schwich (Pierre) [École des Mines (Paris), ex-Corning, Danone, Hewlett-Packard, 3i, Siparex, Next Venture)]
BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, FSI, Bastid, Public
Note: website revamping, in September 2010
note : the company has created a plant division in 2011, as a major diversification | 110.6 | 50.0 | Genome | Preclin |
Cellial Technologies
Profile +
www.cellial.com | 2001 | North-Picardie
Lens | Contract, Research
Key words: CNS research optimization, In vitro cell culture, Blood-Brain Barrier
Mission: accelerate CNS profiling and identify qualified leads candidates and eliminates the botleneck of drug transport accross Blood-Brain Barrier from clients' discovery process
Clients: Pharmaceutical industry, Biotechs, Academic labs
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Leman (Sandrine) [born 1971, Ph.D., Institut Pasteur]
Sc.Dir.-CSO: Berezowski (Vincent) [Ph.D.]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Finorpa, Nord Innovation, Innovam
Note : 2 additional round-table financing in 2007 and 2008 of undisclosed amount | 1.0 | 1.0 | Multiple | Subcontractor |
CellProthera
Profile +
www.cellprothera.com | 2008 | Alsace
Mulhouse | Discovery, Devices
Key words: Cell Therapy, Regeneration, Myocardial tissue
Mission: to develop innovative stem cell therapy for the regeneration of myocardial tissue, allowing prevention of chronic heart failure after myocardial infarction
Clients: not disclosed
Age: 10 year(s) | Personal Venture |
Managing Dir.-CEO: Lataste (Xavier) [born 1949, Ph.D. clinical neurochemistry, M.D., ex-Sandoz, Novartis]
Sc.Dir.-CSO: Hénon (Philippe) [founder, born 1938, M.D. Hematology, IRHT (founder, 1987), University Prof., also Board Chairman]
Oper.Dir.-COO: Jelsch (Jean-Claude) [CNAM, MBA (CPA, Lyon), ex-Ecco, Adecco]
Med.Dir.-CMO : Lataste (Xavier)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, Financière Bendelé, Alsace Business Angels (registered capital 2008 = 0.05 M€) | 1.6 | n.a. | Cardiovasc | Proof-of-Concept |
CellVax
Profile +
www.cellvax-pharma.com | 2001 | IDF
Évry
(near Paris) | Contract, Services
Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model
Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field
Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II)
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology]
Sc.Dir.-CSO: Wei (Ming)
Med.Dir-CMO: Schatz (Christian) [M.D., Pharm.D., ex-Transgène]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
Notes : website again active in 2010 ; no press release (or news) since 2007 | n.a. | n.a. | Cancers | Subcontractor |
Cerenis Therapeutics
Profile +
www.cerenis.com | 2004 | Midi-Pyrénées
Labège
(near Toulouse) | Discovery, Drugs
Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars
Mission: to discover, develop and market next generation HDL therapies
Clients: Prescribers
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier]
Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo]
Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer]
Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers]
Med.Dir.-CMO: Paolini (John F.) [M.D., Ph.D., ex-Merck US, Bayer]
BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical]
Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO | 117.0 | 50.0 | Cardiovasc | Clinical |
CliniGenetics
Profile +
www.clinigenetics.com | 2000 | Méditerranée
Nîmes | Discovery, Drugs
Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics
Mission: to discover new therapeutics for the treatment of cardiovascular, cerebrovascular and lower limb ischemic diseases with a specific emphasis on atherothrombosis
Clients: Prescribers
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Falco (Jean-Louis) [born 1949, also board chairman, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)]
Sc.Dir.-CSO: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): BankInvest
Notes (February 2012) : the company website is unavailable and the URL does not exist any more since 2010, but a legal process with board meeting occurred in August 2010 (still the same, in September 2011) and a board meeting occured in December 2011 and an AGM in August 2012 | n.a. | n.a. | Cardiovasc | Preclin |
Covalab
Profile +
www.covalab.com | 1995 | Rhône-Alpes
Villeurbanne
(near Lyon) | Design, Drugs
(also Design, Diagnostics)
Key words: Immunochemistry, MABs, Polyclonal antibodies
Mission: to supply innovative and unique polyclonal and monoclonal antibodies to third parties, such as universities, research institutes and commercial organisations around the world
Clients: Research labs
Age: 23 year(s) | Personal venture |
Managing Dir.-CEO: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.24 M€)
Communication: no website corporate news since 2005 | n.a. | n.a. | Multiple | Trade |
Cytheris
Profile +
www.cytheris.com | 1999 | IDF
Issy-les-Moulineaux
(near Paris) | Discovery, Immunology
Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin
Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT)
Clients: Prescribers
Age: 19 year(s) | Personal venture |
Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo, Nicox, Trophos]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Vannier (Bertrand)
BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma]
Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion, Caisse de dépôt et placement du Québec (Canada) (registered capital 2006 = 52.5 M€) | 43.3 | 12.0 | Cancers | Clinical |
Cytoo
Profile +
www.cytoo.com | 2008 | Rhône-Alpes
Grenoble | Contract, Research
Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening
Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability
Clients: Pharmaceutical industry
Age: 10 year(s) | Personal venture |
Managing Dir.-CEO: Chatelain (François) [co-founder, born 1965, ex-CEA, Protogene, Life Technologies, Genset, DNAgency]
Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute]
Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, born 1969, Ph.D. biochemistry, Eng. Centrale, ex-CEA]
Fin.Dir.-CFO: Fayand (Laurence) [EM-Lyon (MBA), ex-Fideco, Hewlett-Packard, Alditech, Crocus Technology (co-founder), Beamind]
BusDev: Sharp (William) [also President-CEO Cytoo Inc.]
Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, Jacques Lewinern, Sham and Entrepreneurs Fund | 11.2 | 7.0 | Consumables | Trade |
DBV Technologies
Profile +
www.dbv-technologies.com | 2002 | IDF
Boulogne Billancourt
(near Paris) | Discovery, Diagnostics, Immunotherapy
Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest
Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT)
Clients: Pharmaceutical industry, Food industry, Cosmetics
Age: 16 year(s) | Start-up (speciality pharma company) |
Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics]
Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam]
Pharm.Dir.: Martin (Laurent) [Pharm.D., MBA IAE Paris, ex-Orphan Europe, Galderma, Fournier, Guerbet]
Clin.Dir: Agbotounou (Wence) [Ph.D. pharmacology, MBA ESCP, ex-Quintiles, PRA International]
Fin.Dir.-CFO: Schilansky (David) [Dauphine University, Imperial College London, ex-Ipsen, UBS Warburg, Thomson]
Dvpt. Dir: Ruban (Charles) [ex-Stallergènes, Europgroup Centrale (Lyon), Ms.Sc, Biomedical Engineering (Harvard-M.I.T), MBA (INSEAD)
BusDev:
Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest, Fonds Stratégique d’Investissement (FSI), Public | 59.8 | 40.5 | Allergy | Trade |
Diaxonhit
Profile +
www.diaxonhit.com | 1997 | IDF
Paris | Discovery, Diagnostics
(also, Discovery, Drugs)
Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer
Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease
Clients: Pharmaceutical industry (own development up to phase II)
Age: 20 year(s) | Personal venture |
Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer]
Sc.Dir.-CSO: Pando (Matthew) [Ph.D. molecular biology]
Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management]
C.O.O.: (Diagnostics Division) Barber (Isabelle) [Ph.D. organic chemistry, ex-Isis Pharmaceuticals, Genset, Ortho Clinical Diagnostics (J&J)]
C.O.O.: (Therapeutic Division) Pando (Matthew) [Ph.D. molecular biology]
BusDev:
Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)]
Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public | 106.9 | 4.4 | Genome | Trade |
DNA Therapeutics
Profile +
www.dna-therapeutics.com | 2006 | IDF
Évry
(near Paris) | Discovery, Drugs
Key words: Cancer, siDNA, DNA repair
Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers
Clients: Prescribers
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.]
Sc.Dir.-CSO: Sun (Jian Sheg)
Res.Dir.: Dutreix (Marie) [Ph.D, CNRS (Institut Curie)]
Fin.Dir.-CFO: Cervera (Bruno) [also, Actinnov (CEO), ex-Neurotech]
BusDev:
Financers (Hist.): Blue Medical Investment, Inserm Transfert | 3.4 | 2.2 | Cancers | Preclin |
Domain Therapeutics
Profile +
www.domaintherapeutics.com | 2001 | Alsace
Illkirch Graffenstaden
(near Strasbourg) | Discovery, Drugs
Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer, Parkinson, Alzheimer, Schizophrenia, Diabetes
Mission: to discover and develop new treatments notably (but not only) for neurological and metabolic disorders, with an exclusive focus on GPCR-mediated neurotransmitter modulation
Clients: Prescribers Pharmas and Biotechs (own development up to phase III Preclinical candidate)
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor]
Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly
Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com | 29.3 | 2.1 | CNS | Clinical |
Dynabio
Profile +
www.dynabio.com | 1992 | Méditerranée
Marseille | Design, Diagnostics
Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit
Mission: to develop new immunological tools to improve detection of Pancreatitis-Associated Protein (PAP), as a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract
Clients: Research labs
Age: 26 year(s) | Personal venture |
Managing Dir.-CEO: Broto (Ruben) [born 1937]
Sc.Dir.-CSO:
Oper.Dir.: Slagel (Dean) [born 1970]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
Communication: no website news update since 2006, extremely limited media information since inception | n.a. | n.a. | Multiple | Preclin |
Edelris
Profile +
www.edelris.com | 2005 | Rhône-Alpes
Lyon | Contract, Research
Key words: Screening, Medicinal chemistry, Small molecules, Mimetics, CombiChem
Mission: to design and produce innovative, therapeutically relevant, natural-mimetic screening compounds, in order to accelerate the hit-lead discovery process in pharmaceutical and biotech research organizations
Clients: Pharmaceutical industry
Age: 13 year(s) | Spin-off |
Managing Dir.-CEO: Ortholand (Jean-Yves) [co-founder, born 1965, Ph.D., ex-Bayer, Rhône Poulenc Santé, Merck Santé]
Sc.Dir.-CSO: Greiner (Alfred) [co-founder, Ph.D., ex-Rhône Poulenc]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note: no legal accounting report since 2005 | n.a. | n.a. | Multiple | Subcontractor |
Endotis Pharma
Profile +
www.endotis.com | 2003 | IDF
Romainville
(near Paris) | Discovery, Drugs
Key words: Small-glyco drugs (SGD), Thrombosis, Cancer
Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology
Clients: Prescribers
Age: 15 year(s) | Start-up |
Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo]
Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009]
Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C]
BusDev: Henrard (Denis) [Ph.D. biochemistry , also DHC, ex-BD Medical, Elixir Pharmaceuticals, Johnson & Johnson, Abbott]
Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners | 34.0 | 25.0 | Multiple | Preclin |
Epixis
Profile +
www.epixis.com | 2003 | IDF
Paris | Discovery, Immunology
Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines
Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV
Clients: Pharmaceutical industry
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Dalba (Maria) [born 1967, M.D., Ph.D.]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Génopole 1er Jour | n.a. | n.a. | Virus | Preclin |
ERYtech Pharma
Profile +
www.erytech.com | 2004 | Rhône-Alpes
Lyon | Delivery, Drugs
Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery, Vaccin'Ery, Graspa
Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients
Clients: Prescribers
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Beyen (Gil) [M.Sc. Bioengineering (Belgium), MBA, ex-TiGenix, Arthur D. Little] and Goineau (Pierre-Olivier) [co-founder, born 1967, MBA IAE Lyon, ex-KPMG]
Oper.Dir.:
Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
Pharm.Dir.: Bailly (David) [Pharm.Dr, Chem.Eng. (Montréal), ex-Skyepharma, Aguettant]
Fin.Dir.-CFO:
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys, Idinvest | 22 | 12.0 | Cancers | Clinical |
Eye Tech Care
Profile +
www.eyetechcare.com | 2008 | Rhône-Alpes
Rillieux la Pape (near Lyon) | Development, Devices
Key words: Ultra-sounds, Ophthalmology, Glaucoma, EYEOP1
Mission: to develop a proprietary ultrasound-based procedure for treating eye diseases
Clients: undisclosed
Age: 10 year(s) | Personal venture |
Managing Dir.-CEO: Romano (Fabrizio) [co-founder, born 1962, Vet.D., ex-Edap TMS]
Clin.Dir.: Farcy (Laurent) [co-founder, born 1973, Ms. biochemistry, ex-Medicrea, Sofradim]
Indus.Dir.: Chapuis (Philippe) [co-founder, born 1968, Eng. ESEM Orléans, IAE, ex-Edap TMS]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Crédit Agricole, CEA Valorisation, SHAM | 9.3 | 7.5 | Ophtalmology | Trade |
Flamel Technologies
Profile +
www.flamel.com | 1990 | Rhône-Alpes
Venissieux
(near Lyon) | Delivery, Drugs
(also, Design, Devices)
Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action
Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry
Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry
Age: 28 year(s) | Start-up |
Managing Dir.-CEO: Anderson (Michael S.) [ex-Éclat Pharmaceuticals, KV Pharmaceutical, Ther-Rx Corporation, Schein, A.H. Robins Company]
Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] & Castan (Catherine) [Ph.D.]
Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé]
Fin.Dir.-CFO: Crouzet (Siân) [ex-McCormik, Ernst & Young]
BusDev: Lisi (Steven A.) [ex-Deerfield Mgt, Panacea Asset Mgt, Millenium Partners]
Strat.Comm.Dir.: Mosseri Marlio (Charles)
Financers (Hist.): Public (Nasdaq) | n.a. | n.a. | Multiple | Trade |
Fluofarma
Profile +
www.fluofarma.com | 2003 | Aquitaine
Bordeaux | Contract, Research (also, Contract, Services)
Key words: High Content Screening (HCS), Automated flow cytometry, Cell-based assays
Mission: to provide third parties with High Content Screening (in-cellulo screening) services for target and drug discovery, predictive toxicity testing and cosmetics development
Clients: Pharmaceutical industry, Biotech, Cosmetic industry
Age: 14 year(s) | Spin-off |
Managing Dir.-CEO: Pin (Jean-Baptiste) [founder, born 1974, ex-Ernst & Young Biotechnology]
Sc.Dir.-CSO: Ichas (François) [Ph.D. biomedical sciences, ex-Inserm]
Sales&Mktg.Dir.: Plane (Julie) [ex-Avenium Consulting]
Fin.Dir.-CFO:
BusDev: Brisson (Bruno) [ex-Cellectis, Mauna Kea Technologies, Biospace Lab]
Financers (Hist.): privately owned (registered capital 2006 = 0.24 M€) | n.a. | n.a. | Multiple | Subcontractor |
GemacBio
Profile +
www.gemacbio.com | 1999 | Aquitaine
Berganton, Saint Jean d'Illac
(near Bordeaux) | Development, Diagnostics
(also, Contract, Manufacturing)
Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases
Mission: to develop a wide range of monoclonal and polyclonal antibodies against neurotransmitters, nitrosylated and nitrated amino-acids, bacterial antigens
Clients: Distributors, Pharmaceutical industry, Biotech, Research labs
Age: 18 year(s) | Personal venture |
Managing Dir.-CEO: Lurton (Louis) [born 1956]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): IRDI, ACI, SOCRI, Oséo/Anvar, business angels
Note: the company website has ceased to provide with news since Fall 2009 | n.a. | n.a. | CNS | Trade |
Genepep
Profile +
www.genepep.com | 2003 | Midi-Pyrénées
St Jean de Védas
(near Montpellier) | Contract, Research
(also, Discovery, Drugs)
Key words: Peptides, Transcriptomes, Bio-informatics softwares
Mission: to provide third parties with custom peptide synthesis, antibody production, peptide and protein sequencing, mass spectrometry, and to design own peptides for therapeutic research
Clients: Pharmaceutical industry (own development up to proof of concept)
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS]
Sc.Dir.-CSO: Puget (Karine)
Fin.Dir.-CFO: Chorro (Karine) [HEC (1994), also Deputy CEO]
BusDev:
Financers (Hist.): Sud Angels | n.a. | n.a. | Multiple | Preclin |
Genewave
Profile +
www.genewave.com | 2001 | IDF
Paris | Design, Devices
Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers, HybLive
Mission: to develop, manufacture and market cutting-edge microarray instrumentation for diagnostic, clinical and life science research
Clients: Research labs, Biotech, Other Institutions, OEM markets
Age: 16 year(s) | Personal venture |
President: Desforges (François-Xavier) [born 1960, Ph.D. Electronics, ex-Photonetics]
Managing Dir.-CEO: Choumane (Houtaï) [Ph.D. Optics, also co-CEO]
Sc.Dir.-CSO: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF]
Tech.Dir.-CTO: Rattier (Maxime) [Ph.D., Polytechnique, ex-Luxtera]
Dev.Dir.: Marcy (Yann) [Ph.D., biological physics (Institut Curie)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note: no legal accounting report since 2006, website contents much reduced in October 2012 (e.g. no more news) | n.a. | n.a. | Multiple | Trade |
Genfit
Profile +
www.genfit.com | 1999 | North-Picardie
Lille | Discovery, Drugs
Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes
Mission: to bring therapeutic and diagnostic solutions to combat the major health concerns of diabetes, its associated risk factors, and its complications
Clients: Pharmaceutical industry
Age: 19 year(s) | Start-up |
Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M, also chairman]
Oper.Dir.-COO: Darteil (Raphaël) [Ph.D. molecular and cellular biology, ex-Aventis]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem]
BusDev:
Financers (Hist.): Finorpa, Nord Cration, BP Création, Ya Global, University Lille II, Public | n.a. | 14.0 | Cardiovasc | Clinical |
Genomic Vision
Profile +
www.genomicvision.com | 2004 | IDF
Paris | Discovery, Drugs
(also, Discovery, Diagnostics)
Key words: Diagnostics, Nanotechnology, DNA, Molecular combing
Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases
Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur]
Sc.Dir.-CSO: Conseiller (Emmanuel) [Ph.D., ex-Sanofi-Aventis, Rhône-Poulenc Rorer]
Oper.Dir.-COO: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring]
Fin.Dir.-CFO: Martin (Erwan) [ex-Cytomics (co-founder), Syndex, Université de Marne la Vallée (Professeur, finances)]
BusDev: Abut (Fadilha)
Financers (Hist.): Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital | 6.0 | 4.0 | Multiple | Launch |
GenoSafe
Profile +
www.genosafe.com | 2003 | IDF
Évry
(near Paris) | Contract, Services
Key words: Bio-therapeutics, Drug evaluation
Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties
Clients: Pharmaceutical industry, Biotechs, Research labs
Age: 15 year(s) | Start-up |
Managing Dir.-CEO: Roques (Stéphane) [born 1972, SupdeCo, ex-Arthur Andersen, AFM, Genethon]
Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon]
Fin.Dir.-CFO:
BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon]
Financers (Hist.): A2I (seed), Genethon, AFM | 3.5 | 3.5 | Multiple | Subcontractor |
GenoScience Pharma
Profile +
www.3dgenoscience.com | 2001 | Méditerranée
Marseille | Discovery, Drugs
(also, Contract, Research)
Key words: Antivirals, Protease inhibitor, HCV
Mission: to discover, develop and commercialize novel antiviral products (combining internal expertise in viral infections and unique molecular modeling through GenMol proprietary software (current focus on compounds for the treatment of hepatitis C infections)
Clients: undisclosed
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)]
Sc.Dir.-CSO: Benech (Philippe) [Ph.D., ex-CNRS, founder Genesodi]
Tech.Dir.-CTO: Pépé (Gérard) [Ph.D., Research Director (CNRS)]
Fin.Dir.-CFO: Corroy (Jean-Paul) [Sup de Co, ex-Alphabio]
BusDev:
Financers (Hist.):
Notes : no news on website since 2005 and URL changed from genosciencepharma.com back to old 3dgenoscience.com in 2011 ; legal data show a loss in capital in July 2011 (recurrent) | n.a. | n.a. | Virus | Preclin |
Genoscreen
Profile +
www.genoscreen.fr | 2001 | North-Picardie
Lille | Contract, Research
Key words: DNA, Genome, Sequencing, Genotyping, Mutation detection, Gene expression, Microbial identification, Microbial typing
Mission: to develop and to realize innovative services on all kind of genomes to provide answers that best suit the needs of research laboratories, by using own high throughput equipments
Clients: Pharmaceutical industry, Research labs, Life science industries, Academic research institutions
Age: 17 year(s) | Spin-off |
Managing Dir.-CEO: Tordeux (André) [born 1947]
Sc.Dir.-CSO: Tordeux (André), also Ferreira (Stéphanie) [Ph.D.]
Sales Dir.: Antigny (Frédéric) [M.Sc., MBA]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned | n.a. | n.a. | Genome | Subcontractor |
GenOway
Profile +
www.genoway.com | 1999 | Rhône-Alpes
Lyon | Contract, Research
Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests
Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats)
Clients: Research labs
Age: 19 year(s) | Spin-off |
Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA (HEC)]
Sc.Dir.-CSO:
Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome]
BusDev: Thiam (Kader)
Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public | 10.8 | 1.1 | Genome | Subcontractor |
Genticel
Profile +
www.genticel.com | 2001 | Midi-Pyrénées
Labège
(near Toulouse) | Discovery, Immunology
Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix
Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV)
Clients: Prescribers
Age: 17 year(s) | Spin-off |
Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia]
Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc]
Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon]
BusDev:
Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI
Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder) | 24.0 | 13.1 | Vaccines | Clinical |
GTP Technology
Profile +
www.gtptech.com | 2000 | Midi-Pyrénées
Labège
(near Toulouse) | Contract, Manufacturing
(also, Design, Drugs)
Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers
Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production
Clients: Pharma industry, Biotechs, Research labs
Age: 18 year(s) | Spin-off |
Managing Dir.-CEO: Pease (Christopher) [born 1963, M.Sc. Insa (Lyon), ex-Millipore], also Managing dir. Darlington Life Science
Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology]
Oper.Dir.-COO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology], also chairman
Tech.Dir.-CTO: Mozo (Julien) [Ph.D.]
Fin.Dir.-CFO:
BusDev: Hountondji (Séverine) [M.Sc. Insa]
Financers (Hist.): privately owned, undisclosed | n.a. | 0.45 | Multiple | Subcontractor |
Helios Biosciences
Profile +
www.helios-bioscience.com | 2002 | IDF
Romainville
(near Paris) | Discovery, Targets (also, Contract, Research)
Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway
Mission: to research for own pipeline or to provide third parties with proprietary tools in the identification and characterization of therapeutic targets and biomarkers
Clients: Research labs, Cosmetic and Pharma industries
Age: 16 year(s) | Academic |
Managing Dir.-CEO: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon]
Sc.Dir.-CSO: Dumas (Sylvie) [Ph.D., Normale Sup, ex-CNRS]
Fin.Dir.-CFO:
Med.Dir.-CMO: Vujasinovic (Todor) [M.D., ex-CNRS]
Financers (Hist.): privately owned (registered capital 2006 = 0.15 M€)
Notes: no legal accounting report since 2006 ; the company is facing legal redress since September 12. 2012 ; URL has changed in 2012 from www.helios-biosciences.com to www.helios-bioscience.com (without 's') | n.a. | n.a. | Cancers | Preclin |
Hemarina
Profile +
www.hemarina.com | 2007 | Bretagne
Morlaix | Discovery, Drugs
Key words: Hemoglobin, Blood-transfers, Transfusion, Sea-Invertebrate, Arenicole
Mission: to develop a new generation of oxygen-carrier for therapeutical and industrial applications (to help cope with the huge deficit of blood worldwide), based on extraction and purification from a marine organism
Clients: Pharmaceutical industry (developement limited to early stage), Biotechs
Age: 11 year(s) | Spin-off |
Managing Dir.-CEO: Zal (Franck) [co-founder, born 1966, Ph.D. oceanography, ex-CNRS]
Sc.Dir.-CSO: Zal (Franck)
Techn.Dir.-CTO: Rousselot (Morgane), [co-founder, Ph.D., Eng. ENSCMu, ex-GSK]
Pharm.Dir.: Naccache (Alain) [Pharm.Dr]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately-owned, Inserm Transfert Initiative, Synergie Finance, Vaneau, and various business angels (registered capital 2007 = 0.26 M€) | n.a. | 3.0 | Blood | Preclin |
Hybrigenics
Profile +
www.hybrigenics-services.com | 1998 | IDF
Paris | Discovery, Drugs
(also, Services, Research)
Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions
Clients: Prescribers
Age: 20 year(s) | Academic |
Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
Oper.Dir.-COO: Formstecher (Etienne) [Polytechnique, Ph.D., also deputy CEO]
Tech.Dir.: Rain (Jean-Christophe) [Ph.D. Molecular Genetics, co-founder, also deputy CEO]
I.T.Dir.-CIO: Collura (Vincent) [Ph.D. structural bioinformatics]
Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public
note : in September 2012, the company changes its URL from www.hybrigenics.com to www.hybrigenics-services.com | n.a. | 2.7 | Cancers | Preclin |
Hyphen BioMed
Profile +
www.hyphen-biomed.com | 1999 | IDF
Neuville-sur-Oise
(near Paris) | Design, Diagnostics
(also, Discovery, Diagnostics)
Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest
Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity
Clients: Research labs, Pharmaceutical industry
Age: 19 year(s) | Personal venture |
Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)]
Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago]
Fin.Dir.-CFO:
BusDev (& sales): Penissard (Véronique)
Financers (Hist.): privately owned, IDF Développement, Banque Populaire | n.a. | n.a. | Cardiovasc | Trade |
Imagene
Profile +
www.imagene.fr | 1998 | Aquitaine
Pessac
(near Bordeaux) | Contract, Manufacturing
Key words: DNA-conservation, Encapsulation, Extraction
Mission: to provide third parties with high quality, long term preservation of DNA at room temperature for large scale genomic resources banks
Clients: Research labs
Age: 19 year(s) | Personal venture |
Managing Dir.-CEO: Tuffet (Sophie) [founder, Ph.D. biology]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): OTC A.M. and Aquitaine Création Investissement | n.a. | 2.0 | Genome | Trade |
ImmunId
Profile +
www.immunid.com | 2005 | Rhône-Alpes
Grenoble | Contract, Research
Key words: Personalized diagnostics, Combinatorial Repertoire analysis, Immunology analysis, Immunodeficiency, Immuno-monitoring, T & B cell repertoire, Genomic DNA, Infectious diseases, Auto-immune diseases, Blood cancers, Lymphoma and Leukemia diagnosis, ImmunTracker, ImmunIg
Mission: to provide third parties with innovative diagnostic and prognostic tools and high value-added services to decrease clinical study costs by selecting better immuno-drug candidates and by measuring immuno-reconstitution and suppression kinetics
Clients: Research labs, Hospitals, Pharmaceutical industry
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA]
Sc.Dir.-CSO: Pasqual (Nicolas)
Oper.Dir.-COO: Weisbuch (Sébastien) [born 1977, Ph.D. nanobiology, ex-CEA]
Tech.Dir.-CTO: Mouret (Jean-François) [Pharm.D., ex-Applied Biosystems, Cogenics, Genome Express (co-founder)]
Fin.Dir.-CFO:
BusDev: Plantier (Nadia)
Financers (Hist.): privately owned (registered capital 2006 = 0.053 M€)
Note : website revamped in March 2009 | n.a. | n.a. | Multiple | Trade |
Immutep
Profile +
www.immutep.com | 2001 | IDF
Orsay
(near Paris) | Discovery, Immunology
(also, Discovery, Diagnostics)
Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein
Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases
Clients: Prescribers
Age: 17 year(s) | Spin-off |
Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell]
Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Innoven Partenaires, H2I | 6.7 | 2.5 | Cancers | Clinical |
Imstar
Profile +
www.imstar.fr | 1985 | IDF
Paris | Contract, Services
Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder
Mission: to provide third parties with complete vertical solutions for fully automated high-throughput cellular analysis, in the fields of genotoxicity and environmental toxicity, focused on compound screening, biomonitoring, cytopathology, and dedicated to research, diagnostic, staging and drug discovery
Clients: Research labs
Age: 33 year(s) | Spin-off |
Managing Dir.-CEO: Soussaline (Françoise) [born 1945]
Sc.Dir.-CSO: Soussaline (Françoise)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned | n.a. | n.a. | Studies | Subcontractor |
In-Cell-Art
Profile +
www.incellart.com | 2005 | Bretagne
Nantes | Design, Delivery
(also Discovery, Drugs)
Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection
Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles
Clients: Pharmaceutical industry, Biotechs, Academic labs
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth]
Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm]
Oper.Dir.-COO: Belloc (Chloé) [born 1977, Ph.D., MBA]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€) | 0.45 | 0.25 | Multiple | Preclin |
Indicia Biotechnology
Profile +
www.indicia.fr | 1998 | Rhône-Alpes
Lyon | Contract, Research
Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services
Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents
Clients: Pharmaceutical industry, Diagnostics industry
Age: 20 year(s) | Personal venture |
Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics]
Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2010 = 0.51 M€)
Note : initial company registering under Indicia: 1984.03 | n.a. | n.a. | Studies | Subcontractor |
InGen Biosciences
Profile +
www.ingen.fr | 2001 | IDF
Chilly-Mazarin
(near Paris) | Design, Diagnostics
Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag
Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases
Clients: Pharmaceutical industry
Age: 16 year(s) | Start-up |
Managing Dir.-CEO: Buckle (Isabelle) [Ph.D. microbiology, ex-Applied Biosystems, Ciphergen Biosystems, Amersham Pharmacia Biotech]
Sc.Dir.-CSO: Mignon Godefroy (Karine) [Ph.D, ex-Chemunex, BMD, Bio-Rad]
Oper.Dir.-COO: Mollet (Patrick) [ex-Organon]
Mktg.Dir.: Martin (Jacques) [Eng. ESITPA, ex-Clonatec]
Fin.Dir.-CFO: Elorga (Esteban) [Sup-de-Co, ex-Arhur Andersen]
BusDev:
Financers (Hist.): Innoven Partners, Société Générale A.M.
Notes : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) ; the company is subject of a take over in Novemebr 2012 | 8.0 | 6.0 | Infections | Trade |
Innate Pharma
Profile +
www.innate-pharma.com | 1999 | Méditerranée
Marseille | Discovery, Drugs
Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201
Mission: to develop first in class drugs targeting the innate immune system
Clients: Prescribers
Age: 19 year(s) | Start-up |
Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter]
Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter]
Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS]
Fin.Dir.-CFO: Moukheibir (Catherine) [MBA, ex-Zeltia, Shire, Movetis]
BusDev: Morel (Yannis) [Ph.D. oncology, NormalSup]
Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public | 125.3 | 23.1 | Cancers | Clinical |
InnaVirVax
Profile +
www.innavirvax.fr | 2008 | IDF
Évry
(near Paris) | Discovery, Immunology
(also, Discovery, Diagnostics)
Key words: HIV, CD4 restoration, Predictive test
Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient
Clients: Pharmaceutical industry
Age: 10 year(s) | Start-up |
Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer]
Sc.Dir.-CSO: Crouzet (Joël)
Fin.Dir.-CFO:
Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)]
Financers (Hist.): Pradeyrol Développement, Fa Dièse, CapDecisif Management, Genopole 1er Jour | 6.4 | 3.7 | HIV | Clinical |
Innovative Health Diagnostics
Profile +
www.ihdiag.com | 2009 | Alsace
Strasbourg | Discovery, Diagnostics (also, Contract, Research)
Key words: Alzheimer, Biomarkers, DiagAlz
Mission: to develop and sell diagnostic solutions in the field of neurodegenerative diseases, based on detection of specific biological blood markers
Clients: Prescribers, Hospitals
Age: 9 year(s) | Personal venture |
Managing Dir.-CEO: Regnaut (Xavier) [co-founder, born 1964, Eng. Agro, Ms. Genetics, EMBA HEC]
Sc.Dir.-CSO: de Barry (Jean) [co-founder, Ph.D., Eng. Chemistry, ex-Inserm)
Clin.Dir.-CMO: Sellal (François) [co-founder, M.D., Pharm.D., ex-CM2R]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.05 M€), Oseo, FEDER, Sodiv Alsace
Note : IHD is the trade mark company name | n.a. | n.a. | Alzheimer, | Preclin |
IntegraGen
Profile +
www.integragen.com | 2000 | IDF
Évry
(near Paris) | Discovery, Diagnostics
Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP
Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy
Clients: Prescribers
Age: 18 year(s) | Spin-off |
Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba]
Sc.Dir.-CSO: Liebaert (François) [MBA, ex-Schering, Abbott]
Fin.Dir.-CFO: Riot-Lamotte (Laurence) [CESEM, ex-Aureus-Pharma, Deloitte & Touche, Thomson, Deutsche Telekom France]
SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems]
BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza]
Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM | 23.0 | 6.7 | Cardiovasc | Launch |
Ipsogen
Profile +
www.ipsogen.com | 1999 | Méditerranée
Marseille | Discovery, Diagnostics
Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia
Mission: to design, manufacture and market molecular assays with proven expertise in identifying and translating key discoveries into essential tests intented to support personalized approach to cancer treatment
Clients: Research labs, Prescribers
Age: 19 year(s) | Personal venture |
Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter]
Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS]
Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter]
Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono]
Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge]
SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly]
BusDev:
Financers (Hist.): Samenar (Caisse d'Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public
Note : trade mark logo : «Ipsogen, cancer profiler» | 26.2 | 1.9 | Cancers | Trade |
I-Stem
Profile +
www.istem.eu | 2004 | IDF
Évry
(near Paris) | Discovery, Drugs
(also, Contract, Research)
Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS
Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin
Clients: undisclosed
Age: 13 year(s) | Start-up |
Managing Dir.-CEO: Peschanski (Marc)
Sc.Dir.-CSO: Peschanski (Marc)
Fin.Dir.-CFO: Zakhia (Raymond)
BusDev: Duprat (Sébastien) [born 1975, D.E.A. Biology, ex-ESTOOLS, Scientific Research Helsinki-Lille]
Financers (Hist.): INSERM, AFM (French Muscular Dystrophy Association)
Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008) | n.a. | 7.5 | Multiple | Incub |
Karcinolys
Profile +
www.no-website.net | 2005 | Rhône-Alpes
Lyon | Development, Drugs
Key words: Biologicals, Liver cancer, Pancreatic cancer, Herpes virus
Mission: to develop a new generation of tumour-selective «replication conditional» HSV-1 derived oncolytic viruses
Clients: Pharmaceutical industry
Age: 12 year(s) | Start-up |
Managing Dir.-CEO: Béjot (Jean-Luc) [born 1957, M.D., ex-OPI, Novartis, Quintiles, Genzyme, Ipsen, Cassenne]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.1 M€)
Communication : no website, yet | n.a. | n.a. | Cancers | Incub |
Keosys
Profile +
www.keosys.com | 2001 | Bretagne
Saint Herblay (near Nantes) | Development, Devices
Key words: Nuclear medicine, Digital imaging, Radiology, Mammography, I.T. programmes, Visio+, Positoscope
Mission: to develop new imaging and communication systems for nuclear medicine and radiology
Clients: Distributors or directly to Hospitals, Clinics, Cancer centers, Radiologists
Age: 17 year(s) | Start-up |
Managing Dir.-CEO: Fortineau (Jérôme) [born 1968, co-founder, Eng., ex-Alcatel]
Sc.Dir.-CSO: Terve (Pierre)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Lumiplan, Vizille Capital Innovation (CIC group), Pays de Loire Développement, Sodera
Note: no legal accounting report since 2007 | n.a. | 1.5 | Cancers | Trade |
MABlife
Profile +
http://www.mablife.com | 2000 | IDF
Évry
(near Paris) | Discovery, Drugs
Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis
Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer
Clients: Pharmaceutical industry (own development up to phase II included)
Age: 18 year(s) | Personal venture |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
Sc.Dir.-CSO: Boumsell (Laurence)
Fin.Dir.-CFO: vacant
BusDev: vacant
Financers (Hist.): Génopole 1er Jour, IxCore, Anvar
Notes : full company legal name is Monoclonal Antibodies Therapeutics, up to 2011 ; previous URL was www.matbiopharma.fr ; | 5.8 | 5.8 | Cancers | Clinical |
Magnisense
Profile +
www.magnisense.com | 2003 | IDF
Rosny-sous-Bois (near Paris) | Discovery, Diagnostics
Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo
Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods)
Clients: Diagnostic industry
Age: 15 year(s) | Start-up |
Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little]
Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.]
Fin.Dir.-CFO:
RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.]
BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata]
Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€)
Note : legal foundation, February 20. 2007 (not 2003, as per company) | 7.0 | 1.0 | Point of Care Testing | Trade |
Mapreg
Profile +
www.mapreg.com | 2000 | IDF
Le Kremlin-Bicêtre
(near Paris) | Discovery, Drugs
Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids
Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections
Clients: Pharmaceutical industry (own development up to phase II included)
Age: 17 year(s) | Academic |
Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.]
Managing Dir.-CEO (co-): Villey (Isabelle) [Ph.D., MBA, ex-Vision Institute]
Sc.Dir.-CSO: Robel (Paul) [M.D.]
Oper.Dir.-COO: Baeuerle (Ralf) [PhD]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note: according to the company (November 2012, but website not regularly updated), total raised capital is close to 5 M€. | 2.0 | n.a. | CNS | Clinical |
Mauna Kea Technologies
Profile +
www.maunakeatech.com | 2000 | IDF
Paris | Discovery, Diagnostics
Key words: Fluorescence, Fiber optic, Microscopy, Pneumology, Gastrology, CellVizio
Mission: to develop in vivo cellular imaging systems for biomedical and medical applications
Clients: Specialist doctors
Age: 18 year(s) | Personal venture |
Managing Dir.-CEO: Loiseau (Sacha Alexandre) [co-founder, born 1970, Ph.D., Eng. École Polytechnique, ex-CNES]
Sc.Dir.-CSO: Lacombe (François) [Ph.D. astrophysics, Normale Sup]
Fin.Dir.-CFO: Cohen (Éric) [MBA, ex-Biocortech, Hybrigenics, Teva, Radio BFM]
BusDev:
Financers (Hist.): Psilos Group, Seventure, CreAdev | n.a. | 20.5 | Multiple | Trade |
Medesis Pharma
Profile +
www.medesispharma.com | 2003 | Langeudoc-Roussillon
Baillargues
(near Montpellier) | Discovery, Drugs
Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes, Huntington Disease, Bipolar Disorders
Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology and delivery of nucleic acid (siRNA antisens)
Clients: undisclosed
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)]
Sc.Dir.-CSO: Maurel (Patrick) [Ph.D., ex-Inserm]
Oper.Dir.-COO: Jackson (Peter) [Ph.D.]
Fin.Dir.-CFO:
BusDev: Jackson (Peter)
Financers (Hist.): privately owned | 8.5 | 2.7 | Multiple | Clinical |
Mellitech
Profile +
www.mellitech.com | 2005 | Rhône-Alpes
Grenoble | Discovery, Drugs
(also, Design, Diagnostics)
Key words: Type 2 diabetes, Zinc transporter protein
Mission: to develop a new therapeutic and diagnostic approach to type II diabetes based on a proprietary (PCT) zinc transporter protein, only present in insulin-secreting cells
Clients: undisclosed
Age: 12 year(s) | Spin-off |
Managing Dir.-CEO: Platford (Richard) [Ms. mechanical sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers, Cellvir]
Sc.Dir.-CSO: Chimienti (Fabrice) [Ph.D.]
Oper.Dir.-COO: Girod-Roux (Pierre-Marie) [also board chairman, DEA (Physiology), Ms. management]
Fin.Dir.-CFO:
BusDev: de Boysson (Yann) [co-founder, Engineer]
Financers (Hist.): privately owned (registered capital 2006 = 0.08 M€) | 0.5 | 0.5 | Cardiovasc | Preclin |
Metabolys
Profile +
www.metabolys.org | 2008 | Rhône-Alpes
Lyon | Contract, Research
Key words: Metabolomics, Toxicity, Drug candidate
Mission: to improve the preclinical evaluation of drug candidates through cellular metabolomics in pharmacology, toxicology and nutrition (identification and quantification of metabolic pathways by the combination of enzymatic and carbon 13 NMR measurements with mathematical models of metabolic pathways)
Clients: Pharmaceutical industry, Research labs
Age: 9 year(s) | Spin-off |
Managing Dir.-CEO: Baverel (Gabriel) [born 1947, founder, M.D., University Prof. Lyon]
Sc.Dir.-CSO: Baverel (Gabriel)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2008 = 0.15 M€)
Note: web site, still under construction since inception (May 2011) | 0.15 | 0.15 | Testing | Proof-of-Concept |
MilleGen
Profile +
www.millegen.com | 1999 | Midi-Pyrénées
Labège
(near Toulouse) | Contract, Manufacturing
(also, Development, Drugs)
Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides
Mission: to develop and and genetically engineer new human therapeutic antibodies based on proprietary Directed Molecular Evolution platform, for third parties and for own pipeline (also, to offer custom services including high-throughput DNA sequencing, bioinformatics, gene cloning and vector development services, peptides synthesis and antibodies engineering and production)
Clients: Pharmaceutical industry, Research labs, Biotechs
Age: 18 year(s) | Personal venture |
Managing Dir.-CEO: Kharrat (Abdel Hakim) [co-founder, born 1961, Ph.D. biology, Ms. Management, ex-EMBL Heidelberg]
Sc.Dir.-CSO: Bouayadi (Khalil) [co-founder, Ph.D. molecular pharmacology]
I.T.Dir.-CIO: Crozet (Fabien) [Ph.D. molecular neurobiology]
Fin.Dir.-CFO:
BusDev: Deflisque (Anne) [Ms. biochemistry, ex-GE Healthcare]
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€) | 0.6 | 0.6 | Multiple | Subcontractor |
Murigenetics
Profile +
www.murigenetics.com | 2005 | Méditerranée
Marseille | Discovery, Drugs
Key words: Genetic diseases, Charcot-Marie-Tooth (CMT), Hereditary neuropathy, Genetic mental disorders
Mission: to develop new drugs for the treatment of serious genetic diseases, based on internal production of genetically modified animal models expressing human genes of patients with hereditary peripheral neuropathies, or mental retardation
Clients: Prescribers
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Berro (Marine) [born 1980, ESIL]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): grants by Association Française pour le traitement de la Myopathie (AFM, i.e. French Muscular Dystrophy Association), privately owned (registered capital 2006 = 0.04 M€)
Note : on legal accounts, company have only 1 headcount in 2010 ; at the end of 2011, legal accounts mention 2 headcounts, no revenues and major deficits ; in November 2012, the company website is inactive and the URL dropped | n.a. | n.a. | Genome | Preclin |
NanoBiotix
Profile +
www.nanobiotix.com | 2003 | IDF
Paris | Design, Drugs
Key words: Nanoparticles, Cancer, NanoXray, Nbtxr3
Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles
Clients: Hospitals
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran]
Sc.Dir.-CSO:
Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran]
Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis]
Fin.Dir.-CFO:
BusDev: Mühlenweg (Bernd) [Ph.D. chemistry, Munich, ex-Wilex]
Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management
Note: an IPO is being prepared in Fall 2012 | 16.3 | 8.3 | Cancers | Clinical |
Neorphys
Profile +
www.neorphys.com | 2005 | Méditerranée
Nîmes | Discovery, Drugs
Key words: Nausea-free acute pain, Morphine derivatives, Opioids, Analgesics
Mission: to develop a new family of opioid analgesic drug candidates with low side effects
Clients: Pharmaceutical industry (own development up to phase IIb)
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Lahana (Roger) [co-founder, born 1954, ex-Syntem]
Sc.Dir.-CSO:
Oper.Dir.-COO: Larbouret (Karine) [co-founder, ex-Syntem]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Soridec, Inserm-Transfert, CEA Valorisation, Fa Diese 2, Seillans, plus independent business angels | 2.3 | 1.2 | Multiple | Preclin |
Neovacs
Profile +
www.neovacs.com | 1993 | IDF
Paris | Discovery, Immunology
Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids
Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases
Clients: Prescribers
Age: 25 year(s) | Spin-off |
Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough]
Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute]
Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur]
Fin.Dir.-CFO:
BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting]
Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor]
Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management
note : at the end of December 2010, Novartis shares account for 26.6% | n.a. | 2.6 | Cancers | Clinical |
Netris-Pharma
Profile +
www.no-website.net | 2008 | Rhône-Alpes
Lyon | Discovery, Drugs
Key words: Breast cancer, Metastasis, Dependence receptors, Targeted Therapy
Mission: to develop therapeutic compounds for the treatment of cancer, in particular of breast cancer and NSC Lung cancer
Clients: undisclosed
Age: 10 year(s) | Personal venture |
Managing Dir.-CEO: Bernet (Agnès) [co-founder, born 1968, CNRS]
Sc.Dir.-CSO: Bernet (Agnès)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€) | n.a. | n.a. | Cancers | Proof-of-Concept |
Neuronax
Profile +
www.neuronax.com | 2003 | Centre
Saint Beauzire
(near Clermont-Ferrand) | Discovery, Drugs
(also Contract, Services)
Key words: Neural repair, Parkinson disease, Ataxy, NX peptides
Mission: to develop new drugs for neural repair in cases of neuro-traumas and neuro-degenerative disorders
Clients: Pharmaceutical industry (out-licensing after proof-of-concept)
Age: 15 year(s) | Spin-off |
Managing Dir.-CEO: Gobron (Stéphane) [born 1968]
Sc.Dir.-CSO: Gobron (Stéphane)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) | n.a. | n.a. | CNS | Proof-of-Concept |
NewVectys
Profile +
www.newvectys.com | 2010 | IDF
Paris | Contract, Research
Key words: Gene-Transfer, Vectorology, Translational-Research, Gene-Therapy, Transgenic-Models
Mission: to develop innovative gene transfer technologies and their applications in transgenic large animal models and gene therapy (own research and co-development as subcontractor)
Clients: Pharmaceutical industry, Medical devices industry, Biotechs and CROs
Age: 8 year(s) | Personal venture |
Managing Dir.-CEO: Duboscq (Antoine) [co-founder, born 1968, ex-Procter & Gamble, Boston Consulting Group, WMI]
Sc.Dir.-CSO: Sarkis (Chamsy) [co-founder, born 1974, Ph.D., ex-CNRS]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2011 = 0.25 M€) | n.a. | n.a. | Multiple | Preclin |
NicOx
Profile +
www.nicox.com | 1996 | Méditerranée
Nice | Delivery, Drugs
Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis
Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology
Clients: Prescribers
Age: 22 year(s) | Start-up |
Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco]
Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz]
Fin.Dir.-CFO: Castaldi (Eric)
BusDev: Spencer (Gavin) [Ph.D. chemistry, ex-Novartis, Boots]
Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008) | 380 (over) | 100 | Multiple | Pre-reg |
Nokad
Profile +
www.nokad-technology.com | 2004 | IDF
Évry
(near Paris) | Discovery, Targets
Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals
Mission: to develop and market functional inactivation (knock-out) of secreted endogenous proteins in mammals, through direct in vivo induction of a specific immune response against an endogenous target
Clients: Pharmaceutical industry, Research labs
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Abina (Amine, Mohammed) [co-founder, born 1963, M.D. immunology, Ph.D., ex-AFSSAPS]
Sc.Dir.-CSO: Erard (François) [Ph.D., University Professor, ex-Novartis]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Cap Décisif and Genopole 1er Jour, SHAM (Société Hospitalière d'Assurances Mutuelles), privately owned | n.a. | 1.6 | Studies | Trade |
Nosopharm
Profile +
www.nosopharm.com | 2009 | Méditerranée
Nîmes | Discovery, Drugs
Key words: Anti-infectives, Clostridium difficile, Multi-resistant Gram-negative pathogens
Mission: to discover and develop novel antibiotics against nosocomial and emerging infections
Clients: Biotechs, Pharmaceutical industry (own development up to phase I)
Age: 9 year(s) | Personal venture |
Managing Dir.-CEO: Villain-Guillot (Philippe) [co-founder, born 1977]
Sc.Dir.-CSO: Gualtieri (Maxime) [co-founder, ex-CNRS]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.02 M€) | n.a. | n.a. | Infections | Proof-of-Concept |
NovAliX
Profile +
www.alix-pharma.com | 2002 | Alsace
Strasbourg-Illkirch | Discovery, Drugs
(also Design, Protein)
Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage
Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry
Clients: Research labs
Age: 15 year(s) | Spin-off |
Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC]
Sc.Dir.-CSO: Zeyer (Denis)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
Note: Alix has become, end of 2008, a subsidiary of Novalix, then Alix has been discontinued in 2009 ; no legal reports since 2006 for Novalix (and also Alix) ; Jenn (Stephan) [born 1968] is president of the company | n.a. | n.a. | Multiple | Preclin |
NovoCIB
Profile +
www.novocib.com | 2005 | Rhône-Alpes
Lyon | Contract, Research
(also, Discovery, Drugs)
Key words: Nucleotides, Antivirals, HCV, Enzymes, Precice platform
Mission: to provide third parties with a wide range of products and services, as nucleoside kinase phosphorylation assays, IMPDH or PNP inhibition assays, nucleotides and nucleosides bio-analysis, in cell extract or body fluids (including clinical samples) or the evaluation of the metabolic impact of compounds intended for therapeutic applications in oncology and virology or as immunosuppressive agents, and to develop own anti-viral nucleoside analogues
Clients: Pharmaceutical Industry, Biotechs
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Godard (Nicolas) [Ms. microbiology (INA), MBA]
Sc.Dir.-CSO: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS], also President
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) | n.a. | n.a. | Virus | Subcontractor |
Novotec
Profile +
www.novotec-labs.com | 1997 | Rhône-Alpes
Lyon | Contract, Manufacturing
Key words: Antibodies, Extra cellular matrix (ECM), Tissue-samples, Immunochemistry, Histology
Mission: to develop, produce and distribute species specific antibodies directed against macro-molecules of the Extracellular Matrix (ECM), to prepare tissue analysis
Clients: Pharmaceutical industry, Cosmetic industry, Biotechs, Academic and Industry Research labs
Age: 20 year(s) | Spin-off |
Managing Dir.-CEO: Guerret (Sylviane) [born 1950] et Hartmann (Danielle) [born 1953]
Sc.Dir.-CSO: Hartmann (Daniel)
Fin.Dir.-CFO:
BusDev: Prulière (Franck)
Financers (Hist.): privately owned (registered capital 2006 = 0.065 M€)
Note: no communication policy on web site | n.a. | n.a. | Multiple | Subcontractor |
Obe Therapy
Profile +
www.obetherapy.com | 2000 | IDF
Évry
(near Paris) | Discovery, Targets
(also, Discovery,, Drugs)
Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes
Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype
Clients: Pharmaceutical industry
Age: 18 year(s) | Personal venture |
Managing Dir.-CEO:
Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€)
Note: no communication policy on web site | 0.7 | 0.3 | Cardiovasc | Preclin |
Oligovax
Profile +
www.oligovax.com | 2000 | IDF
Paris | Discovery, Immunology
Key words: Oligo-nucleotides, Immuno-stimulants, Cancer, Liténimod
Mission: to develop innovative anti-cancer therapies belonging to a new therapeutic class, TLR9 agonists
Clients: Prescribers
Age: 18 year(s) | Start-up |
Managing Dir.-CEO: van der Schueren (Paul) [founder, born 1963, MBA]
Sc.Dir.-CSO: Richard (Margaretha) [Pharm.D., ex-Pierre Fabre, AP-HP]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Global Millenium Fund
Communication: no website news update since 2006, no legal information available since end 2005
Note : webhosting with Lycos withdrawn in March 2009 | n.a. | n.a. | Cancers | Clinical |
Oncodesign
Profile +
www.oncodesign.fr | 1995 | Rhône-Alpes
Dijon | Contract, Research
(also, Discovery, Therapies)
Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology
Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies
Clients: Pharmaceutical industry
Age: 23 year(s) | Personal venture |
Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Ewing (Jonathan)
Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille | n.a. | 3.0 | Studies | Subcontractor |
OriBase Pharma
Profile +
www.oribase-pharma.com | 2007 | Méditerranée
Montpellier | Contract, Research
Key words: Computational chemistry, Predictive-interpretative model building, QSAR/QSPR datamining, Structure-Activity relationships, SARA platform
Mission: to provide third parties with medicinal chemistry oriented tools and services (chemo-informatics, molecular modelling and bio-informatics) from Hit Identification to Lead Optimisation
Clients: Pharma industry, Agro industry, and Biotechs
Age: 11 year(s) | Personal venture |
Managing Dir.-CEO: Yasri (Aziz) [co-founder, born 1966, Ph.D. biophysics and drug sciences, ex-Syntem, ArQule, J&J, Nova Decision]
Sc.Dir.-CSO: Yasri (Aziz)
Chem.Dir.: Cazals (Bénédicte) [Ph.D. organic chemistry, ex-Idenix, Azasynth]
I.T.Dir.: Chevé (Gwénaël) [Ph.D. medicinal chemistry, ex-Pierre Fabre]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
Notes : in December 2010, the initial websites of the forming companies are still active under www.novadecision.com and www.azasynth.com ; foundation date of Oribase Pharma selected as that of Azasynth, i.e. only 1 month before Nova Decision | n.a. | n.a. | Studies | Subcontractor |
Oroxcell
Profile +
www.oroxcell.com | 2004 | IDF
Romainville
(near Paris) | Contract, Services (also, Delivery, Drug)
Key words: Skin models (human), Pre-clinical testing, Drug delivery pre-formulation, Innovative formulations, Oral bioavailability
Mission: to conduct preclinical studies (in vitro ADME, Animal PK on rodents, Phys-Chem testing, Bioanalysis) for third parties, plus to develop own research in cell culture and innovative formulations, financed by CRO cash-flow
Clients: Pharmaceutical industry, Research labs, Cosmetic industry, Food industry, Veterinary industry
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Pachot (Jean) [founder, born 1960, Eng. biochemistry, ex-Roussel Uclaf, Aventis]
Sc.Dir.-CSO: Pachot (Jean)
Chem.Dir.-CTO: Dini (Christophe) [born 1962, ex-Roussel Uclaf, Aventis]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.3 M€) | n.a. | n.a. | Studies | Subcontractor |
Oxincell
Profile +
www.oxincell.com | 2006 | Méditerranée
Montpellier | Contract, Services
Key words: Mitochondria, Oxymetry measurement, Toxicology, Antivirals
Mission: to provide third parties with optimized oximetric analysis of mitochondrial activity
Clients: Pharmaceutical industry, Biotechs, Research labs
Age: 12 year(s) | Personal venture |
Managing Dir.-CEO: Peyreigne (Christelle) [co-founder, born 1969, Ph.D. physiology, Inserm]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
Communication: no website news update since 2006 in February 2010 | n.a. | n.a. | Virus | Preclin |
Palumed
Profile +
www.palumed.com | 2000 | Midi-Pyrénées
Toulouse | Discovery, Drugs
Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines
Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases
Clients: Pharmaceutical industry (Sanofi-Aventis)
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Meunier-Chesny (Claudine) [born 1949]
Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris | n.a. | n.a. | Infections | Preclin |
PharmaLeads
Profile +
www.pharmaleads.com | 2000 | IDF
Paris | Design, Drugs
(also, Discovery, Drugs)
Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia
Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay
Clients: Research labs, Pharmaceutical industry
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger]
Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)]
Fin.Dir.-CFO: Maillard (Pierre) [MBA-ESSEC, ex-Dassault Aviation, Suez Environment]
BusDev: Wurm (Michel) [M.D.]
Financers (Hist.): undisclosed | n.a. | n.a. | Multiple | Trade |
Pharnext
Profile +
www.pharnext.com | 2007 | IDF
Paris | Delivery, Drugs
Key words: Drug Repositioning, Charcot Marie Tooth disease, Orphan drugs, Pleotherapy
Mission: to develop innovative treatments for serious neurological diseases, notably peripheral neuropathies (Charcot Marie Tooth, peripheral diabetic neuropathy), and possibly Alzheimer, by implementing a drug repositioning approach which aims to expand the indications for existing medicines
Clients: Prescribers
Age: 11 year(s) | Start-up |
Managing Dir.-CEO: Cohen (Daniel) [co-founder, born 1951, Ph.D., ex-Genset, Millenium]
Sc.Dir.-CSO: Chumakov (Ilya) [Ph.D. chemistry, D.Sc. Molecular Biology, ex-CEPH, Genset, Serono Genetics Institute
Fin.Dir.-CFO: Heidsieck (Loïc) [ex-Arthur Young, Autologic, Franklin Mint, Serono, Genset]
BusDev:
Financers (Hist.): Truffle Capital, Aurinvest, Financière Boscary, Parinvest (Jean-Charles Naouri), Financière Gaspard | 17.8 | 8.0 | Orphan | Clinical |
PhenoPro
Profile +
www.phenopro.com | 2007 | Alsace
Illkirch
(near Strasbourg) | Contract, Services
(also, Contract, Research)
Key words: Translational medicine, Mouse phenotyping, Targets
Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs
Clients: Research labs
Age: 11 year(s) | Spin-off |
Managing Dir.-CEO: Schaeffer (Catherine) [born 1962]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Bocquel (François) [M.D., I.A.E., ex-Erudia, UCB Pharma, Parke Davis, Pfizer
Financers (Hist.): privately owned
Communication: no legal accounting information available since inception | n.a. | n.a. | Studies | Trade |
Pherecydes Pharma
Profile +
www.pherecydes-pharma.com | 2006 | IDF
Romainville
(near Paris) | Discovery, Drugs
Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages
Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company
Clients: undisclosed
Age: 11 year(s) | Spin-off |
Managing Dir.-CEO: Gabard (Jérôme) [born 1961, Ph.D., ex-Marketech, DuPont de Nemours]
Sc.Dir.-CSO: Iris (François) [co-founder]
R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur]
BusDev:
Financers (Hist.): Biosecurity, Financière de Brienne | n.a. | 1.2 | Infections | Preclin |
PolyIntell
Profile +
www.polyintell.com | 2004 | IDF-Normandy
Val-de-Reuil (south Rouen) | Contract, Research
(also, Contract, Manufacture)
Key words: Molecularly Imprinted Polymers, MIP, AFFINIMIP, Intelligent polymers, Selectivity, Solid phase extraction, Purification, Miniaturisation, Hydrogel, Sample preparation, Diagnostics
Mission: to develop, manufacture and market more accurate analytical and diagnostic tools for pharmaceutical R&D and food safety, plus to operate own research in new polymers, financed by CRO cash-flow
Clients: Pharmaceutical industry, Chemical industry, Food industry
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Naraghi (Kaynoush) [co-founder, born 1970, Ph.D., Ms. management]
Sc.Dir.-CSO: Bayoudh (Sami) [co-founder, Ph.D.]
Oper.Dir.-COO: Arotçarena (Michel) [Ph.D.]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned | 0.8 | 0.8 | Studies | Subcontractor |
Proteogenix
Profile +
www.proteogenix-antibody.com | 2003 | Alsace
Oberhausbergen
(near Strasbourg) | Discovery, Diagnostics
(also Contract, Services)
Key words: Custom Antibodies, Recombinant proteins, Peptide synthesis, Gene synthesis, Cancer screening, Biomarkers
Mission: to discover new diagnostic markers in cancer through targeted screenings and to provide third parties with polyclonal and monoclonal antibody development, recombinant protein production and purification, gene synthesis and peptide synthesis
Clients: Research labs
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Funfrock (Philippe) [co-founder, born 1978]
Sc.Dir.-CSO: Hopfner (Raphaël)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Oséo, privately owned
Note : Proteogenix will move in brand new state of the art facilities by 2011 | 0.04 | 0.04 | Cancers | Trade |
Protexel
Profile +
www.no-website.net | 2000 | IDF
Paris | Discovery, Drugs
Key words: Immunology, Alcoholic hepatitis, Liver cancer, Cirrhosis, Chemical mimetics, Anti-oxydant, Superoxyde dismutase, Mangafodipir
Mission: to develop innovative treatments for severe liver conditions
Clients: Pharmaceutical industry (own development up to phase III)
Age: 18 year(s) | Spin-off |
Managing Dir.-CEO: Batteux (Frédéric) [Batteux (Arman), born 1939, legally as President]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note : no Company website since inception | n.a. | n.a. | Liver | Clinical |
PX'Therapeutics
Profile +
www.px-therapeutics.com | 2000 | Rhône-Alpes
Grenoble | Contract; Research
(also, Contract, Manufacturing)
Key words: Recombinant protein engineering
Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein'eXpert, PX'Monoclonals and PX'Pharma, for third parties
Clients: Pharmaceutical industry, Biotechs
Age: 17 year(s) | Personal venture |
Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology]
Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology]
Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.]
Fin.Dir.-CFO:
BusDev: Untereiner (Claire)
Financers (Hist.): Vizille Capita (and others), privately owned (registered capital 2007= 0.13 M€) | n.a. | 1.3 | Multiple | Trade |
Quantum Genomics
Profile +
www.quantum-genomics.com | 2006 | IDF
Massy
(near Paris / HQ
Jersey City
USA) | Discovery, Drugs
Key words: Academic, Development platform, Co-partnering R&D
Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases
Clients: Pharmaceutical industry
Age: 12 year(s) | Start-up |
Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM]
Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): | 4.0 | 1.0 | Multiple | Preclin |
Rhenovia Pharma
Profile +
www.rhenovia.com | 2007 | Alsace
Mulhouse | Contract, Research
Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory
Mission: to contribute to discover new medicines against Alzheimer's and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions
Clients: Pharmaceutical industry, Biotechs
Age: 11 year(s) | Personal venture |
Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis]
Sc.Dir.-CSO: Baudry (Michel) [co-founder, born 1948, Eng. Ecole Polytechnique, Prof. engineering (Los Angeles), Ph.D.]
Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis]
Fin.Dir.-CFO:
BusDev: George (Florian) [Ph.D. chemistry]
Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€) | 1.0 | 1.0 | CNS | Proof-of-Concept |
ScarCell Therapeutics
Profile +
www.scarcell-therapeutics.com | 2007 | IDF
Paris | Design, Drugs
Key words: Cell therapy project, Transplantation, Cardiovascular
Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others
Clients: undisclosed
Age: 11 year(s) | Spin-off |
Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note : URL not renewed in time (October 2009), still unavailable (February, May, October 2010, April 2011, December 2012), but legally company still active (with a new President since July 2012, Laurent Cezard, born March 1969 | n.a. | n.a. | Cardiovasc | Proof-of-Concept |
Sisène Biotechnologies
Profile +
www.no-website.net | 2007 | IDF
Paris | Discovery, Drugs
Key words: Cancer, Vegf, Anti-angiogenics, Ophtalmology
Mission: to discover and develop new anti-angiogenic biotherapies, in cancers and ophtalmology
Clients: Pharmaceutical industry (own development up to clinical trials)
Age: 11 year(s) | Academic |
Managing Dir.-CEO: Marsac (Jean) [born 1943, co-founder, M.D., Professor]
Sc.Dir.-CSO: Plouët (Jean) [deceased, co-founder, M.D., Ph.D., Professor, Inserm, ex-Abtech, Gencell, AP-HP Lariboisière]
Oper.Dir.-COO: Garreau (Martine) [born 1951, M.D., ex-Synthelabo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): ARC, ANR, InCA
Note (November 2011) : the new company website is available | 1.3 | 1.3 | Cancers | Preclin |
Skuld-Tech
Profile +
www.skuldtech.com | 1999 | Méditerranée
Montpellier | Design, Diagnostics
(also, contract, research)
Key words: Biomarkers, Genomics, Pharmaco-genomics, Bio-informatics, Biosensors, SAGE
Mission: to select and validate biomarkers, bioinformatics, biosensors, leading to design new diagnosis, identify new targets, and generate new leads for biopharmaceutical companies and personalized medicine
Clients: Research labs
Age: 19 year(s) | Spin-off |
Managing Dir.-CEO: Ritter (Didier) [co-founder, born 1969, Ms. molecular biology, MBA, ex-Bio2R (founder)]
Sc.Dir.-CSO: Piquemal (David) [co-founder, Ph.D., Prof. genomics]
Fin.Dir.-CFO: Outrebon (Philippe) [co-founder, Ms. sciences, ex-Ernst & Young]
BusDev: Outrebon (Philippe)
Financers (Hist.): Oseo, Regional Territory Body, Private Investors | n.a. | n.a. | Multiple | Preclin |
Stentys
Profile +
www.stentys.com | 2006 | IDF
Paris | Design, Devices
Key words: Stent, Heart-Attack, Revascularisation,
Mission: to develop a new generation of self-expanding stents or self-apposing stents, specialized in the treatment of heart attacks (or Acute Myocardial Infarction)
Clients: Device Industry, Hospitals
Age: 12 year(s) | Start-up |
Managing Dir.-CEO: Issenmann (Gonzague) [co-founder, born 1972, MBA, ex-CordisJ&J]
Sc.Dir.-CSO:
Med.Dir.: Spaargaren (René) [M.D., Medtronic, Boston Scientific, EV3]
Mktg&Sales: Goffart (Lucien) [MBA, ex-J&J, Abbott , Volcano]
Fin.Dir.-CFO: Piot (Stanislas) [Ms. finance and economics, ex-Ipsogen, Banque Worms, Crédit Lyonnais, Oddo, Natixis]
BusDev:
Financers (Hist.): Sofinnova Partners, Scottish Equity Partners, Crédit Agricole Private Equity, FSI, Public (registered capital 2009 = 0.16 M€) | 74.9 | 36.0 | Cardiovasc | Trade |
Synapcell
Profile +
www.synapcell.com | 2005 | Rhône-Alpes
Grenoble | Contract, Research
Key words: Preclinical development, CNS, Epilepsy, Neuronal networks
Mission: to provide third parties with customized solutions for preclinical evaluation of CNS therapeutics and with consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry, and also to develop own research innovative tools
Clients: Research labs
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Roucard (Corinne) [born 1969, co-founder, Ph.D., ex-Synapcell (Project Leader)]
Sc.Dir.-CSO: Bressand (Karine) [born 1971, Ph.D.]
Fin.Dir.-CFO: Roche (Yann) [born 1974, Ph.D. biology, Ms. Management]
BusDev: Roche (Yann)
Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€) | n.a. | 0.7 | CNS | Subcontractor |
Synprosis
Profile +
www.synprosis.com | 2003 | Méditerranée
Fuveau
(near Marseille) | Discovery, Immunology
(also Contract, Manufacturing)
Key words: HIV1 vaccine, Synthetic peptides
Mission: to provide custom peptide synthesis (notably vaccines) in solid phase manufacture with high quality for basic research and for therapeutic applications (cGMP) and to develop own immunological compounds
Clients: Pharmaceutical industry
Age: 15 year(s) | Personal venture |
Managing Dir.-CEO: Salles (Jean-Pierre) [born 1954, Pharm.D., ex-Laphal (Dir. R&D)]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Pomarède (Richard)
Financers (Hist.): privately owned (registered capital 2007 = 0.23 M€) | 0.35 | 0.2 | Vaccines | Preclin |
Tc Land Expression
Profile +
www.tcland-expression.com | 2002 | Bretagne
Nantes | Design, Diagnostics
Key words: Biomarkers, Transplantation, Auto-immune diseases
Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine
Clients: Pharmaceutical industry, Research labs
Age: 15 year(s) | Spin-off |
Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder), Diatos (CEO)]
Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)]
Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK]
Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital]
SalesMktg: Kazek (Elodie) [Pharm.D., ESSEC, ex-BioMerieux, Fresenius Kabi, Merck KgAa]
BusDev: Payne (Peter) [Ms. pharmacology, ex-Quintiles, Wellcome, Sterling Drug, Glaxo], also Head of US-Business
Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen
Note: the previous URL, tcland-biotech.com, has been replaced by tcland-expression.com, late 2010 | 9.0 | 8.2 | Multiple | Preclin |
Theraclion
Profile +
www.theraclion.fr | 2004 | IDF
Paris | Development, Devices
Key words: Ultrasound, Parathyroidism, Prostate cancer, Fibroadenoma, UNIS
Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the non-invasive ablation of small tumors and the treatment of secondary hyperparathyroidism, thyroid nodules
Clients: undisclosed
Age: 14 year(s) | Start-up |
Managing Dir.-CEO: Burel (Jean-Yves) [born 1951, ex-GE Healthcare]
Sc.Dir.-CSO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer]
R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)]
Fin.Dir.-CFO:
BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare]
Financers (Hist.): Truffle Ventures | 8.6 | 1.6 | Multiple | Clinical |
Theradiag
Profile +
www.theradiag.com | 1987 | IDF
Marne-la-Vallée
(near Paris) | Discovery, Diagnostics
(also, Design, Devices)
Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex
Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases
Clients: Pharmaceutical industry
Age: 31 year(s) | Start-up |
Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Neovacs, Carmat, Flamel Technologies, Aventis]
Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux
Sc.Dir.-CSO:
Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, Seroa]
Admin.Dir.: François (Fabienne) [MBA, HR experience]
BusDev:
Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova
Communication:with company name change, the URL moves and www.bmd-net.com is deleted (June 2012) | 11.2 | 8.2 | Allergy | Trade |
Theralpha
Profile +
www.theralpha.com | 2009 | Méditerranée
Sophia Antipolis
(near Nice) | Discovery, Drugs
Key words: Pain, Acid-Sensing-Ion-Channel (ASIC), Sublingual
Mission: to develop innovative peptide-based drugs for the treatment pain
Clients: Pharmaceutical industry (own development up to clinical trials)
Age: 9 year(s) | Spin-off |
Managing Dir.-CEO: Dellamonica (David) [ESG, MBA, ex-TxCell, Nex&Com, Polygram Universal, Ogilvy Healthcare]
Sc.Dir.-CSO: Lazdunski (Michel) [Ph.D., Professor, CNRS]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€) | n.a. | n.a. | Pain | Preclin |
TheraVectys
Profile +
www.theravectys.com | 2005 | IDF
Paris | Discovery, Immunology
Key words: Vaccines, DNA Flap Lentivirus, Veterinary
Mission: to develop new vaccines derived from the DNA Flap Lentivirus technology
Clients: Pharmaceutical industry (own development up to clinical trials)
Age: 13 year(s) | Spin-off |
Managing Dir.-CEO: Gohaud (Romain) [born 1949]
Sc.Dir.-CSO: Charneau (Pierre) [Ph.D. virology, Institut Pasteur]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) | n.a. | n.a. | Vaccines | Preclin |
Transgene
Profile +
www.transgene.fr/us | 1979 | Alsace
Strasbourg | Discovery, Immunology
Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases
Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products
Clients: Prescribers
Age: 39 year(s) | Start-up |
Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux]
Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome]
Med.Dir.-CMO: Adda (Nathalie) [M.D., ex-Vertex]
Fin.Dir.-CFO: Boissel (Stéphane) [MBA (Chicago), ex-PWC, Innate Pharma, Lazard]
BusDev:
Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public | 350 (over) | 100.1 | Vaccines | Clinical |
Trophos
Profile +
www.trophos.com | 1999 | Méditerranée
Marseille | Discovery, Drugs
Key words: Embryonic neurones, Parkinson's diseases, Huntington's diseases, Cardiac ischemia, IRIstop
Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection)
Clients: Prescribers
Age: 19 year(s) | Personal venture |
Managing Dir.-CEO: Placet (Christine) [Sup de Co (Marseille), ex-Ernst & Young]
Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo]
Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre]
Fin.Dir.-CFO:
BusDev: Harris (Stephen) [Ph.D., ex-GSK]
Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels | 68.0 | 10.0 | Multiple | Clinical |
TxCell
Profile +
www.txcell.com | 2001 | Méditerranée
Sophia Antipolis
(near Nice) | Discovery, Immunology
Key words: Cell Therapy, Inflammatory, Autoimmune diseases
Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn's disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body
Clients: Prescribers
Age: 17 year(s) | Spin-off |
Managing Dir.-CEO: Meyer (François) [born 1948, Ph.D. molecular biology, ex-Ciba-Geigy, Sandoz, Rhone Poulenc Rorer, Aventis]
Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm]
Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB]
Fin.Dir.-CFO: Sarlot (Christophe)
BusDev:
Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert | 21.0 | 10.5 | Inflammation | Clinical |
UROsphere
Profile +
www.urosphere.com | 2004 | Midi-Pyrénées
Labège
(near Toulouse) | Contract, Research
Key words: Urinary incontinence, Benign prostatic hyperplasia (BPH), Sexual dysfunctions, Renal disorders
Mission: to provide third parties with research preclinical services for urology and renal pathologies
Clients: Pharmaceutical industry
Age: 14 year(s) | Spin-off |
Managing Dir.-CEO: Lluel (Philippe) [born 1966, Ph.D. pharmacology]
Sc.Dir.-CSO: Palea (Stefano) [born 1962, Ph.D. pharmaceutical chemistry, ex-Sanofi-Aventis, Glaxo-Wellcome]
Fin.Dir.-CFO:
BusDev:
HR.Dir: Mignotte-Darmon (Brigitte) [DESS Management]
Financers (Hist.): privately owned (registered capital 2006 = 0.13 M€)
note (March 2010) : new website unveiled | n.a. | n.a. | Multiple | Preclin |
Vaxon Biotech
Profile +
www.vaxon-biotech.com | 2004 | IDF
Paris | Discovery, Immunology
Key words: Therapeutic vaccines, Cryptic peptides
Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides
Clients: Prescribers
Age: 14 year(s) | Personal venture |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned | n.a. | n.a. | Vaccines | Clinical |
Vectalys
Profile +
www.vectalys.com | 2005 | Midi-Pyrénées
Labège
(near Toulouse) | Design, Drugs
(also, Contract, Resarch)
Key words: Gene sequences, Gene transfer, Viral vector, Retrovirus, Lentivirus
Mission: to provide third parties with a platform of retroviral (RV), lentiviral (LV) and adeno-associated virus (AAV) based vectors that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins
Clients: Pharmaceutical industry
Age: 13 year(s) | Personal venture |
Managing Dir.-CEO: Bouillé (Pascale) [born 1967, founder, Ph.D. molecular biology, secretary JEInnov]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): pricately owned (registered capital 2006 = 0.05 M€) | n.a. | n.a. | Virus | Preclin |
Vivalis
Profile +
www.vivalis.com | 1999 | Bretagne
Nantes | Design, Manufacture
(also, Discovery, Immunology)
Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture, EB66
Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases (also deeply involved in veterinarian vaccines)
Clients: Pharmaceutical industry (own development up to clinical trials)
Age: 19 year(s) | Start-up |
Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA]
Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux]
Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas]
BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene]
Financers (Hist.): Grimaud-La Corbière Group, Public
Note : company legal domiciliation : Roussay (49) | 39.5 | 29.0 | Multiple | Preclin |
XenTech
Profile +
www.xentech.eu | 2006 | IDF
Évry
(near Paris) | Contract, Research
(also, Discovery, Diagnostics)
Key words: Theranostics, Preclinical oncology, Tumor models
Mission: to provide specialized services in predictive preclinical oncology, to develop own treatment diagnostics derived from patient-derived tumor xenografts
Clients: Pharmaceutical industry, Biotechs, Research labs
Age: 12 year(s) | Spin-off |
Managing Dir.-CEO: Coulomb (Bertrand) [born 1955, Pharm.D., ex-Nycomed, Altana Pharma, Pasteur-Sanofi Diagnostics, UPSA (BMS), Servier]
Sc.Dir.-CSO: Judde (Jean-Gabriel) [co-founder, born 1954, Ph.D., ex-MD Anderson Cancer Center, NCI, Institut Curie, also board chairman]
Oper.Dir.-COO: Leuraud (Pascal) [co-founder, Ph.D.]
Fin.Dir.-CFO:
BusDev: Bazzacco (Paola)
Financers (Hist.): privately owned (registered capital 2007 = 0.05 M€), Aurinvest Capital 2 | 0.6 | 0.6 | Cancers | Preclin |
